Essential Thrombocythemia: High Platelet Count and Clot Risk

Essential thrombocythemia is a chronic blood cancer in which the bone marrow overproduces platelets, the cell fragments responsible for clotting. Platelet counts in affected people often climb well above the normal upper limit of around 450,000 per microliter, sometimes exceeding a million. Paradoxically, the disease raises the risk of both abnormal clotting and abnormal bleeding, a duality that shapes virtually every treatment decision. First described in 1934, ET belongs to a family of conditions called myeloproliferative neoplasms, and while it progresses slowly enough that many people live decades after diagnosis, its management requires careful, individualized attention.

What Drives the Overproduction of Platelets

In most people with ET, the problem traces to a single acquired mutation in a bone marrow stem cell. The mutation causes megakaryocytes, the large marrow cells that shed platelets into the bloodstream, to multiply unchecked. Three “driver” mutations account for the vast majority of cases. The JAK2 V617F mutation appears in roughly half to 60 percent of ET patients, making it the most common culprit.¹ Mutations in the CALR gene (calreticulin) account for most of the remaining cases, and these work by generating a mutant protein that hijacks the thrombopoietin receptor and drives megakaryocyte growth.² A smaller fraction carry mutations in MPL, the gene encoding the thrombopoietin receptor itself.

About 10 to 15 percent of ET patients test negative for all three canonical mutations, a group referred to as “triple negative.” Even in these cases, the disease is rarely without a genetic fingerprint. A study of 40 triple-negative patients found that the vast majority still harbored mutations in other genes, most commonly TET2 (in over half of patients) and KIT.³ Separate work has identified rare noncanonical driver mutations in genes like THPO and atypical variants of JAK2 and MPL, and some of these turned out to be inherited rather than acquired.⁴ The practical upshot is that knowing which mutation you carry matters: it influences how doctors estimate your risk, which treatments they recommend, and how they distinguish ET from closely related conditions.

Symptoms People Actually Experience

Many people with ET feel perfectly fine at diagnosis and learn they have the disease only after a routine blood test shows an unexpectedly high platelet count. When symptoms do appear, they tend to be a mix of the vague and the distinctive. Fatigue is consistently the most reported complaint, and research into quality of life among ET patients identifies it as the single strongest driver of reduced well-being.⁵ Numbness and tingling in the hands and feet, bone pain, abdominal discomfort, and unintended weight loss also erode quality of life. Women and people who have lived with the disease longer tend to report a higher symptom burden.

One symptom with a strong link to ET is erythromelalgia: episodes of burning pain, redness, and warmth in the hands or feet. Research has shown that this happens because overactive platelets clump inside the tiny arteries supplying the extremities, damaging the vessel lining. Aspirin reliably resolves erythromelalgia in ET because it blocks the platelet enzyme cyclooxygenase, which produces the thromboxane needed for these micro-clots to form. Blood thinners like heparin and warfarin, by contrast, do not help, because the clumping does not depend on the thrombin-driven clotting cascade.⁶ The same platelet-activation mechanism can also trigger brief, transient neurological symptoms like visual disturbances, headaches, and fleeting episodes that mimic small strokes.⁷

The Clotting-and-Bleeding Paradox

ET is a disease of too many platelets, so it makes intuitive sense that it raises clotting risk. What surprises many patients is that it can also cause dangerous bleeding, sometimes at the same time. The explanation lies in what happens when platelet counts climb very high. At extreme levels, often above a million per microliter, the excess platelets chew through von Willebrand factor, a large protein that acts as a glue between platelets and damaged blood vessel walls. The result is a condition called acquired von Willebrand syndrome, which mimics the inherited bleeding disorder.⁸ Patients with higher platelet counts show measurably lower levels of the large von Willebrand factor multimers needed for effective clotting.⁹

This paradox affects treatment decisions directly. A patient with very high platelets and acquired von Willebrand syndrome may actually be harmed by aspirin, because the anti-clotting drug worsens bleeding risk when the natural clotting glue is already depleted. Doctors typically check von Willebrand factor activity before prescribing aspirin in patients whose counts exceed a million. The goal is to bring platelets down to a range where both risks are manageable, not to chase a specific number for its own sake.

How Doctors Estimate Your Thrombosis Risk

Not everyone with ET faces the same odds of a blood clot, and risk stratification guides which patients need platelet-lowering medication and which can be monitored with aspirin alone. The revised International Prognostic Score of Thrombosis for ET (IPSET-thrombosis) sorts patients into four risk tiers: very low, low, intermediate, and high. A large validation study of 585 patients confirmed that the score reliably separates risk levels, with meaningful jumps in clot rates between tiers. In that analysis, the two strongest independent predictors of future clots were the JAK2 V617F mutation and a history of prior thrombosis.¹⁰

The risk categories generally work like this:

Very low risk: younger patients with no JAK2 mutation and no prior clots. Observation alone or low-dose aspirin may suffice.
Low risk: patients carrying JAK2 but without prior clots or older age. Low-dose aspirin is standard.
Intermediate risk: older patients or those with cardiovascular risk factors but no JAK2 mutation. Treatment is debated and individualized.
High risk: anyone with a prior blood clot or older patients with JAK2. Platelet-lowering medication is typically recommended on top of aspirin.

Age over 60 and JAK2 status do most of the heavy lifting in this scoring system. A 35-year-old CALR-positive patient with no clot history lands in a very different category than a 70-year-old JAK2-positive patient who has already had a stroke, and their treatments will reflect that gap.

Cytoreductive Treatment Options

When platelet-lowering medication is needed, hydroxyurea is the first-line choice for most patients. A landmark randomized trial compared hydroxyurea to no cytoreductive therapy in high-risk ET patients and found a dramatic difference: roughly 4 percent of the hydroxyurea group experienced a thrombotic event, compared with 24 percent in the control group.¹¹ Hydroxyurea works by broadly suppressing marrow activity, which brings platelet counts down but also affects white and red blood cell production. It is taken as a daily pill, and most people tolerate it well, though mouth ulcers, skin changes, and low blood counts can occur.

Anagrelide is the main alternative. Unlike hydroxyurea, it targets megakaryocyte maturation more selectively and lowers platelets without suppressing other blood cell lines as much. In a head-to-head trial, however, anagrelide combined with aspirin performed worse than hydroxyurea combined with aspirin on a composite of clotting, bleeding, and progression to myelofibrosis.¹² A meta-analysis pooling data from several studies found that the two drugs were similar at preventing clots, but hydroxyurea came out ahead on a composite of thrombosis, major bleeding, and death, largely because of lower bleeding rates.¹³ A more recent meta-analysis confirmed that anagrelide lowers platelet counts more aggressively but without a clear overall advantage.¹⁴ In practice, anagrelide is used mainly in patients who cannot tolerate or do not respond to hydroxyurea.

Interferons, particularly pegylated forms, represent a third option that has gained traction in recent years. Interferon can reduce the mutant clone itself over time, not just the platelet count, which makes it especially appealing for younger patients who will be on therapy for decades. It is also the only cytoreductive therapy generally considered safe in pregnancy. The main drawbacks are side effects like flu-like symptoms, mood changes, and autoimmune reactions, which cause a meaningful share of patients to discontinue it.

Pregnancy and ET

ET affects women slightly more often than men, and because it can be diagnosed at any age, pregnancy is a common concern. The data are sobering but not hopeless. A retrospective study found that about a third of pregnancies in women with ET ended in miscarriage, compared with roughly 8 percent in a matched control group.¹⁵ A larger analysis of 121 pregnancies in 52 women with ET reported a 69 percent live birth rate, with spontaneous abortion occurring in about a quarter of pregnancies. Aspirin use was associated with a significantly lower odds of complications, while a history of prior pregnancy loss raised the odds substantially.¹⁶

Treatment during pregnancy matters enormously. A systematic review found that women who received no antiplatelet or cytoreductive therapy had a live birth rate of only about 41 percent, while those on low-dose aspirin alone saw rates around 75 percent. Combination approaches, such as aspirin plus low-molecular-weight heparin or aspirin plus interferon, pushed live birth rates above 80 percent.¹⁷ Platelet counts tend to drop naturally during pregnancy, falling by about 43 percent on average with a nadir around delivery, and women whose counts dropped more experienced fewer complications.¹⁸ For women planning a pregnancy, close coordination between a hematologist and an obstetrician from before conception is critical.

When ET Transforms Into Something Worse

Most people with ET live with a slow, manageable disease for many years. But a small fraction will see their disease evolve into myelofibrosis, in which the marrow fills with scar tissue and can no longer produce blood cells effectively, or into acute myeloid leukemia, a fast-moving bone marrow cancer. The risk of leukemic transformation is low overall, but it rises with advancing age, very high platelet counts, anemia, elevated white cell counts, and the presence of certain high-risk mutations like TP53 and EZH2.¹⁹ When leukemic transformation does occur, the outlook is much grimmer than with de novo leukemia. Median survival for MPN-related blast phase ranges from a few months with supportive care alone to under a year with chemotherapy. Allogeneic stem cell transplant offers the only real chance at long-term survival, though three-year survival rates after transplant range from roughly 16 to 33 percent.

These numbers are worth keeping in perspective. For the average ET patient, the annual risk of transformation is quite low, and many people live for decades without any progression. The statistics on blast-phase outcomes describe the unfortunate minority, not the typical course.

ET in Children and Adolescents

ET is genuinely rare in kids, and when it does occur, it looks different from the adult version. A much smaller proportion of pediatric patients carry one of the three main driver mutations; only about 25 to 40 percent test positive, compared with the roughly 85 to 90 percent in adults.²⁰ The majority of children are triple negative, which complicates diagnosis since the adult criteria do not fit cleanly. A French study of 17 pediatric patients (15 with ET) found that 59 percent were triple negative and 41 percent had no symptoms at all at diagnosis.²¹

The good news is that pediatric ET appears more benign, at least within the first few decades after diagnosis. Thrombotic events are rare in children, and bleeding, when it happens, is usually minor. The challenge is treatment: committing a child to lifelong drug therapy carries its own risks. Many pediatric hematologists now advocate for a cautious, watch-and-wait approach with therapeutic de-escalation, reserving cytoreductive drugs for children who actually develop complications. There are no dedicated pediatric guidelines, which means care relies heavily on adult protocols adapted by experience, and physicians who treat these patients consistently report a need for more training and cooperative research.

Surgery and Perioperative Considerations

If you have ET and face elective surgery, your hematologist and surgeon need to coordinate carefully. The dual risk of clotting and bleeding that defines ET becomes particularly dangerous around procedures. Current recommendations advise postponing elective surgery in high-risk or symptomatic patients until platelet counts are brought below 400,000 per microliter and coexisting cardiovascular risk factors are addressed.²² Cytoreductive therapy is the usual method for lowering counts before a planned procedure, though plateletpheresis, a mechanical procedure to physically remove platelets from the blood, can be considered in emergencies when there is no time for medication to work. Compression stockings and pharmacological blood-clot prevention are also part of the perioperative toolkit.

The key point for patients is to disclose your ET diagnosis to any surgeon or anesthesiologist well before any planned procedure, including dental surgery. A platelet count that looks “just a little high” to a surgeon unfamiliar with ET may represent a meaningfully elevated risk that requires specific preparation.

The Financial Side of Living With ET

Chronic blood cancers are expensive, even when they progress slowly. A Canadian population study of over 3,400 ET patients found that mean annual healthcare costs were roughly $16,600 per patient, compared with about $7,000 for age- and sex-matched controls. The biggest cost driver was acute hospital care, accounting for more than half of total spending. Older age, male sex, higher overall illness burden, and a history of venous blood clots all independently predicted higher costs.²³ A separate U.S. study reported even higher numbers, with total annual costs for ET patients averaging nearly $30,000, versus about $8,000 for matched comparisons.²⁴ These figures reflect not just the disease itself but the downstream consequences of complications, hospitalizations for clotting events, and the cumulative cost of lifelong monitoring.

Emerging Therapies Targeting the Root Cause

Current treatments manage ET by keeping platelet counts in check, but they generally do not eliminate the mutant clone responsible for the disease. That is starting to change, at least for patients with CALR mutations. Because mutant calreticulin creates a distinctive protein on the surface of the abnormal cells, it acts as a molecular target that the immune system can theoretically recognize. Researchers are now developing monoclonal antibodies, bispecific antibodies, cancer vaccines, chimeric antigen receptor (CAR) T-cell therapies, and antibody-drug conjugates all aimed specifically at mutant CALR.²⁵ The appeal of these approaches is clonal selectivity: rather than suppressing the entire marrow, they would selectively destroy the diseased cells while leaving healthy blood production intact.

Most of these strategies are still in preclinical stages or early trials, so they are not yet a practical option. But they represent a meaningful conceptual shift from symptom control toward something closer to disease modification or even cure. JAK2-mutated ET does not yet have as neat a surface target, so parallel efforts there are more focused on optimizing interferon therapy, which can reduce the JAK2-mutant clone burden over years of treatment. For now, the landscape is one of cautious optimism: the tools to actually attack the biology of ET are becoming real, even if they have not yet arrived in the clinic for most patients.